A mixed-effects model repeated measures approach (MMRM)	analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA)	HAMD17 total score,	24403	24586	In the case of the HAMD17 total score, advantages for duloxetine over placebo at endpoint (Week 9) from MMRM in Studies 1 and 2 were 4.86 (p < .001) and 2.17 (p = .024), respectively.
A mixed-effects model repeated measures approach (MMRM)	analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA)	Standard errors	25273	25431	Standard errors from LOCF_ANCOVA were approximately 5% smaller than the Week 9 standard errors from MMRM for both the HAMD17 total score and VAS overall pain.
